University of Illinois

Miodrag Radulovacki

David W Carley

The present invention relates generally to pharmacological methods for the amelioration of sleep-related breathing disorders via administration of inhibitors of endocannabinoid membrane transport and combinations thereof.

Functional role for cannabinoids in autonomic stability during sleep

This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or a combination of prostanoid receptor antagonists (eg. ramatroban, ifetroban, diphloretin, phosphate, polyphloretin phosphate, seratrodast, SC19220). The prostanoid receptor antagonist or combination of prostanoid receptor antagonists can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabinoids receptor agonists, one or more serotonin reuptake inhibitors, one or more noradrenalin reuptake inhibitors, a combination of reuptake inhibitors, an inhibitor of prostanoid synthesis, or any combination of the foregoing.

Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists

The present invention relates to a method for preventing or ameliorating a sleep-related breathing disorder. The method involves the use of one or a combination of cholecystokinin (CCK) receptor antagonists.

Methods for treating sleep disorders by cholecystokinin (CCK) receptor B antagonists

A method of ameliorating a sleep-related breathing disorder via administration of at least one cannabimimetic agent, such as oleamide or &#x394;THC, to an individual in need of treatment.

Method for treating sleep apnea

The present invention relates to pharmacological methods for the amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacological activity.

Pharmacological treatment for sleep apnea

The present invention relates to pharmacological methods for the prevention or amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess glutamate-related and/or glycine-related pharmacological activity or that modulate the release of glutamate, glycine, or both from nerve terminals with the central nervous system.

Neuropharmacological treatment of sleep-related breathing disorders

The present invention relates generally to pharmacological methods for the prevention of amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacological activity.

The present invention relates generally to pharmacological methods for the prevention or amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess glutamate-related and/or glycine-related pharmacological activity or that modulate the release of either glutamate or glycine (or both) from nerve terminals with the central nervous system.

Neuropharmacological treatments of sleep-related breathing disorders

A hypnotic composition and method of inducing sleep in a mammal by administering to a mammal in a pharmaceutical carrier a hypnotically effective dose of a salt of 2-amino-3-(1-naphthyl) propanoic acid in the form of an injectable solution, capsule tablet or syrup.

Growing community of inventors

Chicago, IL, United States of America

Miodrag Radulovacki